Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts

Mohammad A. Al-Haddad, Thomas Kowalski, Ali Siddiqui, Howard R. Mertz, Damien Mallat, Nadim Haddad, Nidhi Malhotra, Brett Sadowski, Mark J. Lybik, Sandeep N Patel, Emuejevoke Okoh, Laura Rosenkranz, Michael Karasik, Michael Golioto, Jeffrey Linder, Marc F. Catalano

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background and study aims: Current diagnostic testing is inadequate to determine the malignant potential of pancreatic cysts, resulting in overcautious patient management. Integrated molecular pathology (IMP) testing combines molecular analysis with first-line test results (cytology, imaging, and fluid chemistry) to assess the malignant potential of pancreatic cysts. This multicenter study aimed to determine the diagnostic accuracy of IMP for pancreatic adenocarcinoma, and the utility of IMP testing under current guideline recommendations for managing pancreatic cysts. Patients and methods: Patients who had undergone previous IMP testing as prescribed by their physician and for whom clinical outcomes were available from retrospective record review were included (n=492). Performance was determined by correlation between clinical outcome and previous IMP diagnosis (benign/statistically indolent vs. statistically higher risk [SHR]/ aggressive) or an International Consensus Guideline (Sendai 2012) criteria model for surveillance vs. surgery. The Cox proportional hazards model determined hazard ratios for malignancy. Results: Benign and statistically indolent IMP diagnoses had a 97% probability of benign follow-up for up to 7 years and 8 months from initial IMP testing. SHR and aggressive diagnoses had relative hazard ratios for malignancy of 30.8 and 76.3, respectively (both P93% probability of benign follow-up, with relative hazard ratios for SHR and aggressive IMP diagnoses of 16.1 and 50.2, respectively (both P

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalEndoscopy
Volume47
Issue number2
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Pancreatic Cyst
Molecular Pathology
Guidelines
Proportional Hazards Models
Multicenter Studies
Cell Biology
Neoplasms
Adenocarcinoma
Physicians

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Al-Haddad, M. A., Kowalski, T., Siddiqui, A., Mertz, H. R., Mallat, D., Haddad, N., ... Catalano, M. F. (2015). Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy, 47(2), 136-142. https://doi.org/10.1055/s-0034-1390742

Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. / Al-Haddad, Mohammad A.; Kowalski, Thomas; Siddiqui, Ali; Mertz, Howard R.; Mallat, Damien; Haddad, Nadim; Malhotra, Nidhi; Sadowski, Brett; Lybik, Mark J.; Patel, Sandeep N; Okoh, Emuejevoke; Rosenkranz, Laura; Karasik, Michael; Golioto, Michael; Linder, Jeffrey; Catalano, Marc F.

In: Endoscopy, Vol. 47, No. 2, 2015, p. 136-142.

Research output: Contribution to journalArticle

Al-Haddad, MA, Kowalski, T, Siddiqui, A, Mertz, HR, Mallat, D, Haddad, N, Malhotra, N, Sadowski, B, Lybik, MJ, Patel, SN, Okoh, E, Rosenkranz, L, Karasik, M, Golioto, M, Linder, J & Catalano, MF 2015, 'Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts', Endoscopy, vol. 47, no. 2, pp. 136-142. https://doi.org/10.1055/s-0034-1390742
Al-Haddad MA, Kowalski T, Siddiqui A, Mertz HR, Mallat D, Haddad N et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-142. https://doi.org/10.1055/s-0034-1390742
Al-Haddad, Mohammad A. ; Kowalski, Thomas ; Siddiqui, Ali ; Mertz, Howard R. ; Mallat, Damien ; Haddad, Nadim ; Malhotra, Nidhi ; Sadowski, Brett ; Lybik, Mark J. ; Patel, Sandeep N ; Okoh, Emuejevoke ; Rosenkranz, Laura ; Karasik, Michael ; Golioto, Michael ; Linder, Jeffrey ; Catalano, Marc F. / Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. In: Endoscopy. 2015 ; Vol. 47, No. 2. pp. 136-142.
@article{0e28aa043e0e4f59b97549421a119f67,
title = "Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts",
abstract = "Background and study aims: Current diagnostic testing is inadequate to determine the malignant potential of pancreatic cysts, resulting in overcautious patient management. Integrated molecular pathology (IMP) testing combines molecular analysis with first-line test results (cytology, imaging, and fluid chemistry) to assess the malignant potential of pancreatic cysts. This multicenter study aimed to determine the diagnostic accuracy of IMP for pancreatic adenocarcinoma, and the utility of IMP testing under current guideline recommendations for managing pancreatic cysts. Patients and methods: Patients who had undergone previous IMP testing as prescribed by their physician and for whom clinical outcomes were available from retrospective record review were included (n=492). Performance was determined by correlation between clinical outcome and previous IMP diagnosis (benign/statistically indolent vs. statistically higher risk [SHR]/ aggressive) or an International Consensus Guideline (Sendai 2012) criteria model for surveillance vs. surgery. The Cox proportional hazards model determined hazard ratios for malignancy. Results: Benign and statistically indolent IMP diagnoses had a 97{\%} probability of benign follow-up for up to 7 years and 8 months from initial IMP testing. SHR and aggressive diagnoses had relative hazard ratios for malignancy of 30.8 and 76.3, respectively (both P93{\%} probability of benign follow-up, with relative hazard ratios for SHR and aggressive IMP diagnoses of 16.1 and 50.2, respectively (both P",
author = "Al-Haddad, {Mohammad A.} and Thomas Kowalski and Ali Siddiqui and Mertz, {Howard R.} and Damien Mallat and Nadim Haddad and Nidhi Malhotra and Brett Sadowski and Lybik, {Mark J.} and Patel, {Sandeep N} and Emuejevoke Okoh and Laura Rosenkranz and Michael Karasik and Michael Golioto and Jeffrey Linder and Catalano, {Marc F.}",
year = "2015",
doi = "10.1055/s-0034-1390742",
language = "English (US)",
volume = "47",
pages = "136--142",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "2",

}

TY - JOUR

T1 - Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts

AU - Al-Haddad, Mohammad A.

AU - Kowalski, Thomas

AU - Siddiqui, Ali

AU - Mertz, Howard R.

AU - Mallat, Damien

AU - Haddad, Nadim

AU - Malhotra, Nidhi

AU - Sadowski, Brett

AU - Lybik, Mark J.

AU - Patel, Sandeep N

AU - Okoh, Emuejevoke

AU - Rosenkranz, Laura

AU - Karasik, Michael

AU - Golioto, Michael

AU - Linder, Jeffrey

AU - Catalano, Marc F.

PY - 2015

Y1 - 2015

N2 - Background and study aims: Current diagnostic testing is inadequate to determine the malignant potential of pancreatic cysts, resulting in overcautious patient management. Integrated molecular pathology (IMP) testing combines molecular analysis with first-line test results (cytology, imaging, and fluid chemistry) to assess the malignant potential of pancreatic cysts. This multicenter study aimed to determine the diagnostic accuracy of IMP for pancreatic adenocarcinoma, and the utility of IMP testing under current guideline recommendations for managing pancreatic cysts. Patients and methods: Patients who had undergone previous IMP testing as prescribed by their physician and for whom clinical outcomes were available from retrospective record review were included (n=492). Performance was determined by correlation between clinical outcome and previous IMP diagnosis (benign/statistically indolent vs. statistically higher risk [SHR]/ aggressive) or an International Consensus Guideline (Sendai 2012) criteria model for surveillance vs. surgery. The Cox proportional hazards model determined hazard ratios for malignancy. Results: Benign and statistically indolent IMP diagnoses had a 97% probability of benign follow-up for up to 7 years and 8 months from initial IMP testing. SHR and aggressive diagnoses had relative hazard ratios for malignancy of 30.8 and 76.3, respectively (both P93% probability of benign follow-up, with relative hazard ratios for SHR and aggressive IMP diagnoses of 16.1 and 50.2, respectively (both P

AB - Background and study aims: Current diagnostic testing is inadequate to determine the malignant potential of pancreatic cysts, resulting in overcautious patient management. Integrated molecular pathology (IMP) testing combines molecular analysis with first-line test results (cytology, imaging, and fluid chemistry) to assess the malignant potential of pancreatic cysts. This multicenter study aimed to determine the diagnostic accuracy of IMP for pancreatic adenocarcinoma, and the utility of IMP testing under current guideline recommendations for managing pancreatic cysts. Patients and methods: Patients who had undergone previous IMP testing as prescribed by their physician and for whom clinical outcomes were available from retrospective record review were included (n=492). Performance was determined by correlation between clinical outcome and previous IMP diagnosis (benign/statistically indolent vs. statistically higher risk [SHR]/ aggressive) or an International Consensus Guideline (Sendai 2012) criteria model for surveillance vs. surgery. The Cox proportional hazards model determined hazard ratios for malignancy. Results: Benign and statistically indolent IMP diagnoses had a 97% probability of benign follow-up for up to 7 years and 8 months from initial IMP testing. SHR and aggressive diagnoses had relative hazard ratios for malignancy of 30.8 and 76.3, respectively (both P93% probability of benign follow-up, with relative hazard ratios for SHR and aggressive IMP diagnoses of 16.1 and 50.2, respectively (both P

UR - http://www.scopus.com/inward/record.url?scp=84964308511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964308511&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1390742

DO - 10.1055/s-0034-1390742

M3 - Article

C2 - 25314329

AN - SCOPUS:84964308511

VL - 47

SP - 136

EP - 142

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 2

ER -